IL2 and non-small cell lung carcinoma: Here, they summarize a Phase I clinical trial of TKD/IL-2-stimulated autologous NK cells with NSCLC and describe an ongoing Phase II clinical trial of TKD/IL-2-stimulated NK cells for the treatment of patients with NSCLC, following radiochemotherapy (Specht et al.).